On September 8, CHINA LIFE fell 3.14% in regular trading, trading at 29.60 HKD/share, with turnover of 733 million HKD, extending the broader insurance sector weakness from the prior session.

On the news front, the Ministry of Finance announced on September 6 a 350 billion RMB capital injection into China Life Group, the largest single tranche within a combined 700 billion RMB injection plan targeting five state-owned insurers. While the injection aims to strengthen capital adequacy and risk resilience, the insurance sector has sold off on a classic buy-the-rumor-sell-the-news pattern since the announcement landed. Peers including Ping An fell 1.51%, NCI fell 2.65%, and Sunshine Insurance fell 3.63%, reflecting broad sector weakness.

JPMorgan noted that dilution risk from the injection is relatively low and recommended accumulating CHINA LIFE on weakness, citing a 2027 estimated P/E of 5x and a 4% dividend yield. The company reported robust first-half results with net profit attributable to shareholders of 134.49 billion RMB, surging 228.6% year-over-year, though near-term sentiment remains pressured as the market digests the capital injection event.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)